Loading... Please wait... Loading... Please wait...
ESTIMATED
04/24/2024
04/24/2024
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 4 | -$0.28 | -$0.28 | -$0.28 |
| Q2 2024 | 10 | -$0.33 | -$0.17 | -$0.26 |
| Q3 2024 | 4 | -$0.28 | -$0.28 | -$0.28 |
| Q4 2024 | 4 | -$0.29 | -$0.29 | -$0.29 |
| Q1 2025 | 5 | -$0.29 | -$0.29 | -$0.29 |
| Q2 2025 | 5 | -$0.31 | -$0.31 | -$0.31 |
| Q3 2025 | 5 | -$0.35 | -$0.35 | -$0.35 |
| Q4 2025 | 5 | -$0.37 | -$0.37 | -$0.37 |
| Q1 2026 | 4 | -$0.27 | -$0.27 | -$0.27 |
| Q2 2026 | 4 | -$0.27 | -$0.27 | -$0.27 |
| Q3 2026 | 4 | -$0.29 | -$0.29 | -$0.29 |
| Q4 2026 | 4 | -$0.29 | -$0.29 | -$0.29 |
| Q1 2027 | 4 | -$0.36 | -$0.36 | -$0.36 |
| Q2 2027 | 4 | -$0.43 | -$0.43 | -$0.43 |
| Q3 2027 | 4 | -$0.48 | -$0.48 | -$0.48 |
| Q4 2027 | 4 | -$0.49 | -$0.49 | -$0.49 |
Viking Therapeutics, Inc. last posted its earnings results on Wednesday, April 24th, 2024. The company reported $-0.26 earnings per share for the quarter, topping analysts' consensus estimates of $-0.27 by $0.01. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Viking Therapeutics, Inc. has generated $-1 earnings per share over the last year ($-0.91 diluted earnings per share) and currently has a price-to-earnings ratio of -55.71. Viking Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, July 24th, 2024 based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 04/24/2024 | Q1 2024 | -$0.26 | $0 | $0 | 02/07/2024 | Q4 2023 | -$0.25 | -$0.25 | 0 | $0 | $436,000 | 10/25/2023 | Q3 2023 | -$0.22 | -$0.23 | -0.01 | $0 | 07/26/2023 | Q2 2023 | -$0.21 | -$0.19 | 0.02 | $0 | 04/26/2023 | Q1 2023 | -$0.24 | -$0.24 | 0 | $0 | 02/09/2023 | Q4 2022 | -$0.25 | $0 | 10/26/2022 | Q3 2022 | -$0.23 | -$0.20 | 0.03 | $0 | 07/27/2022 | Q2 2022 | -$0.21 | -$0.23 | -0.02 | $0 | 04/27/2022 | Q1 2022 | -$0.20 | -$0.21 | -0.01 | $0 | 02/09/2022 | Q4 2021 | -$0.19 | -$0.16 | 0.03 | $0 | 11/03/2021 | Q3 2021 | -$0.21 | -$0.17 | 0.04 | $0 | 07/28/2021 | Q2 2021 | -$0.19 | -$0.20 | -0.01 | $0 | 04/28/2021 | Q1 2021 | -$0.18 | -$0.19 | -0.01 | $0 | 02/17/2021 | Q4 2020 | -$0.15 | -$0.15 | 0 | $0 | 10/28/2020 | Q3 2020 | -$0.15 | -$0.13 | 0.02 | $3.15 M | $0 | 07/29/2020 | Q2 2020 | -$0.14 | -$0.13 | 0.01 | $3.04 M | $0 | 04/30/2020 | Q1 2020 | -$0.12 | -$0.13 | -0.01 | $0 | 02/26/2020 | Q4 2019 | -$0.13 | -$0.10 | 0.03 | $0 | 11/05/2019 | Q3 2019 | -$0.13 | -$0.08 | 0.05 | $0 | 08/01/2019 | Q2 2019 | -$0.09 | -$0.11 | -0.02 | $0 |
|---|
A. Viking Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, July 24th, 2024 based off last year's report dates.
A. In the previous quarter, Viking Therapeutics, Inc. (NASDAQ:VKTX) reported $-0.26 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.27 by $0.01.
A. The conference call for Viking Therapeutics, Inc.'s latest earnings report can be listened to online.
A. The conference call transcript for Viking Therapeutics, Inc.'s latest earnings report can be read online.
A. Viking Therapeutics, Inc. (NASDAQ:VKTX) has a recorded net income of $0. Viking Therapeutics, Inc. has generated $-0.91 earnings per share over the last four quarters.
A. Viking Therapeutics, Inc. (NASDAQ:VKTX) has a price-to-earnings ratio of -55.71 and price/earnings-to-growth ratio is 16.34.
